Next Article in Journal
Characterization of the Pinus massoniana Transcriptional Response to Bursaphelenchus xylophilus Infection Using Suppression Subtractive Hybridization
Next Article in Special Issue
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
Previous Article in Journal
Danger Control Programs Cause Tissue Injury and Remodeling
Previous Article in Special Issue
Current Status of Biomarkers for Prostate Cancer
Int. J. Mol. Sci. 2013, 14(6), 11347-11355; doi:10.3390/ijms140611347

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

1,*  and 1
Received: 1 April 2013 / Revised: 21 May 2013 / Accepted: 23 May 2013 / Published: 28 May 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [309 KB, uploaded 19 June 2014]   |   Browse Figures


PCA3 (prostate cancer gene 3) and multiparametric 3 tesla MRI are new promising diagnostic tools in the detection of PCa. Our aim was to study the clinical value of the Progensa PCA3-test: its predictive value for biopsy outcome, Gleason score and MRI outcome. We evaluated, retrospectively, 591 patients who underwent a Progensa PCA3-test at the Radboud University Nijmegen Medical Centre between May 2006 and December 2009. Prostate biopsies were performed in 290 patients; a multiparametric 3 tesla MRI of the prostate was performed in 163/591 patients. The PCA3-score was correlated to biopsy results and MRI outcome. The results show that PCA3 was highly predictive for biopsy outcome (p < 0.001); there was no correlation with the Gleason score upon biopsy (p = 0.194). The PCA3-score of patients with a suspicious region for PCa on MRI was significantly higher (p < 0.001) than in patients with no suspicious region on MRI (52 vs. 21). In conclusion, PCA3 is a valuable diagnostic biomarker for PCa; it did not correlate with the Gleason score. Furthermore, multiparametric MRI outcome was significantly correlated with the PCA3-score. Thus, PCA3 could be used to select patients that require MRI. However, in patients with a negative PCA3 and high clinical suspicion of PCa, a multiparametric MRI should also be done.
Keywords: prostate cancer; PCA3; MRI prostate cancer; PCA3; MRI
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Leyten, G.H.J.M.; Wierenga, E.A.; Sedelaar, J.P.M.; van Oort, I.M.; Futterer, J.J.; Barentsz, J.O.; Schalken, J.A.; Mulders, P.F.A. Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. Int. J. Mol. Sci. 2013, 14, 11347-11355.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert